Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
19 Février 2025 - 12:56PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2025
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
February 19, 2025
2
Exhibit 99.1
Form 604
Corporations Act 2001
Section
671B
Notice of change of interests
of substantial holder
To Company Name/Scheme |
|
Alterity
Therapeutics Limited |
ACN/ARSN |
|
080
699 065 |
1. Details of substantial holder (1)
Name |
|
The
Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity),(together BNYMC Group) |
ACN/ARSN (if applicable) |
|
|
|
There was a change in the interests of the substantial holder on |
|
17/February/2025 |
The previous notice was given to the company on |
|
04/February/2025 |
The previous notice was dated |
|
03/February/2025 |
2. Previous and present voting power
The total number of votes attached to all the voting
shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in
when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities (4) |
Previous notice |
Present notice |
|
Person’s votes |
Voting power (5) |
Person’s votes |
Voting power (5) |
Ordinary shares |
2,266,681,474 |
41.28% |
2,260,546,474* |
33.96%* |
|
|
|
*See Note 1 in Annexure C |
|
3. Changes in relevant interests
Particulars of each change in, or change in the nature
of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial
holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change |
Person whose relevant interest changed |
Nature of change (6) |
Consideration given in relation to change (7) |
Class and number of securities affected |
Person’s votes affected |
See Annexure
B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4. Present relevant interests
Particulars of each relevant interest of the substantial
holder in voting securities after the change are as follows:
Holder of relevant interest |
Registered holder of securities |
Person entitled to be registered as holder (8) |
Nature of relevant interest (6) |
Class and number of securities |
Person’s votes |
See Annexure
C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5. Changes in association
The persons who have become associates (2) of, ceased
to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests
in the company or scheme are as follows:
Name and ACN/ARSN (if applicable) |
Nature of association |
BNYMC
and each Group Entity |
Each Group Entity is an associate of BNYMC pursuant
to section 12(2)(a) of the Corporations Act 2001 (Cth) as each entity is directly or indirectly owned and controlled by BNYMC. |
|
|
6. Addresses
The addresses of persons named in this form are as follows:
Name |
Address |
The
Bank of New York Mellon Corporation |
240
Greenwich Street, New York, NY 10286 USA |
Each
Group Entity |
240
Greenwich Street, New York, NY 10286 USA |
print name |
Andrew Weiser |
|
capacity |
Attorney-In-Fact |
|
|
|
|
|
sign here |
/s/ Andrew Weiser |
|
date |
18/February/2025 |
Annexure
A
This
is Annexure A of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon
Corporation and its related bodies corporate.
The Bank of New York Mellon Corporation
is the ultimate parent company of a corporate group comprised of a large number of operating and holding companies. Details of the entities
directly owned and controlled by The Bank of New York Mellon Corporation are listed below.
| · | The Bank of New York Mellon |
print name |
Andrew Weiser |
|
capacity |
Attorney-In-Fact |
|
|
|
|
|
sign here |
/s/ Andrew Weiser |
|
date |
18/February/2025 |
Annexure B
This is Annexure B
of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon
Corporation and its related bodies corporate
Changes in relevant interests
Date
of change |
Person
whose relevant interest changed |
Nature
of Change |
Consideration given in
relation to change |
Class and number
of
securities affected
(Ordinary Shares) |
Person’s
votes affected |
4-Feb-2025 |
The Bank of New York Mellon |
Transfer Out of securities |
N/A |
(9,732,000) |
(9,732,000) |
5-Feb-2025 |
The Bank of New York Mellon |
Transfer Out of securities |
N/A |
(3,600,000) |
(3,600,000) |
5-Feb-2025 |
The Bank of New York Mellon |
Deposit of securities |
N/A |
2,697,000 |
2,697,000 |
13-Feb-2025 |
The Bank of New York Mellon |
Deposit of securities |
N/A |
4,500,000 |
4,500,000 |
Print Name - |
Andrew Weiser |
|
Capacity - |
Attorney-In-Fact |
|
|
|
|
|
Sign Here |
/s/ Andrew Weiser |
|
Date - |
18 February 2025 |
Annexure C
This
is Annexure C of 2 pages referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon
Corporation and its related bodies corporate
Present
relevant interests
Holder of relevant interest |
Nature of relevant interest |
Class and number of securities |
The Bank of New York Mellon (BNYM) |
Remote Interest Held Under Deposit Agreement
Relevant interest under section 608(1)(c) of the Corporations
Act 2001 (Cth) arising from BNYM having the limited power to dispose of, or control the exercise of a power to dispose of, securities
deposited with or held by BNYM (or its custodian or agent) in its capacity as depositary administering an ADR program for Alterity
Therapeutics Limited (Company) under the Deposit Agreement dated January 2, 2008 between the Company, holders of American depositary
receipts (ADRs) and BNYM (Deposit Agreement). [*See Note 1 below]. |
2,260,545,748
ordinary shares |
BNYMC Group (other than BNYM) |
Relevant interest under section 608(3)(a) and/or section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNYMC Group is above 20%, or that each other entity in the BNYMC Group controls. [*See Note 1 and Note 2 below] |
2,260,545,748
ordinary shares |
Pershing LLC |
Relevant interest under sections 608(1) of the Corporations Act 2001 (Cth) arising from Pershing LLC being the registered owner of the securities. |
726 ordinary shares |
BNYMC Group (other than Pershing LLC) |
Relevant interest under section 608(3)(a) and/or section
608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely Pershing LLC) in which the
voting power of each other entity in the BNYMC Group is above 20%, or that each other entity in the BNYMC Group controls.
[*See Note 2 below] |
726 ordinary shares |
NOTES:
*Note 1:
Of the total of 2,260,546,474 securities in which the BNYMC Group
has a relevant interest, BNYM has a relevant interest in 2,260,545,748 securities
as depositary for Alterity Therapeutics Limited ADR program administered
under the Deposit Agreement. BNYM’s relevant interest in these securities arises as a result of the Deposit Agreement containing rights
for BNYM to dispose of securities held under the ADR program in limited circumstances. Under the Deposit Agreement, ADR holders retain
their rights to dispose of those securities and to give voting instructions for the exercise of voting rights attached to the securities.
BNYMC Group’s power to vote or dispose of these securities is qualified accordingly.
*Note
2: Each Group Entity is a direct or indirect wholly owned subsidiary of BNYMC, the ultimate parent company. Other than BNYM
in respect of 2,260,545,748 securities (of which BNYM’s power to
only dispose of 2,260,545,748 securities is limited – see
Note 1), and Pershing LLC in respect of 726 securities, none of
the BNYMC Group entities are entitled to be registered as holder of the securities and their power to vote or dispose of the securities
is qualified accordingly.
print name |
Andrew Weiser |
capacity |
Attorney-In-Fact |
|
|
|
sign here |
/s/ Andrew Weiser |
|
date |
18/February/2025 |
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025